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Phage display technology using filamen-
tous bacteriophage offers a new way of
selecting specific antibodies from an anti-
body library. A library of large diversity
can be constructed using a human naïve
repertoire, circumventing the need for
immunisation. This method allows the
isolation of monoclonal antibody frag-
ments against a large range of different
antigens, including peptides, proteogly-
cans, proteins, nucleic acids and sugars
and even cell surface antigens/receptors
of organisms. Phage display is a quick
and inexpensive method of antibody pro-
duction. Since no immunisation is
required, it overcomes the problem of
having an animal house and a Home
Office licence. The availability of
libraries comprising human antibody
encoding genes implies that fragments
isolated may have not only diagnostic
but also therapeutic uses. Antibody 
production using traditional hybridoma
technology takes a minimum of 5-6
months; phage display on the other hand
allows isolation of antibodies within
three weeks. More interesting from 
our point of view is the ability to 
isolate various antibodies from a ‘single
pot’ and having similar selection running
simultaneously to act as control.
Preparation of a Phage Library
Blood is collected from a pool of healthy
individuals, lymphocytes are harvested
and mRNA is extracted from them.
Reverse transcriptase PCR (RT-PCR)
using specific primers then amplifies the
specific antibody variable regions. Kits are
available to enable these fragments to be
manipulated and subcloned into ‘phage
display vectors’ to produce a library. Each
phage molecule will carry DNA encoding
a light and heavy chain fragment. The
system is designed so that expression of
the antibody genes results in the produc-
tion, in the Tg1 strain of Escherichia coli,
of antibody fragments fused to the pIII
protein of the bacteriophage.
Panning methodology for
antigen selection
Since the library is designed so that each
phage expresses an individual antibody
fragment, we need to select for those
expressing antibody of interest. As the
pIII protein is expressed on the surface of
the phage itself, we can select for phage
expressing antibody of interest using a
simple panning technique.
The E coli is infected with phage and
the broth culture is incubated in a
shaking waterbath to allow the phage to
infect and multiply in E coli. The phage
is then harvested purified and added to
immobilised antigen of interest and incu-
bated for several hours. After incubation,
the suspension is poured off, and the
antigen washed to remove the unbound
phage. The bound phage, expressing the
antibody of interest, is then eluted and
amplified by growing in E coli.
The process of panning is repeated
three to four times. In the final round of
panning, the phage is used to infect E
coli and then these infected cells are
plated at low density to allow individual
clones to be harvested: one colony con-
tains the progeny of one bacterium
which in turn carries one phage and
hence one antibody type – a monoclonal
antibody. These isolated colonies can be
used to mass produce the phage display
antibodies which may be used directly in
antigen detection. However, the presence
of the phage can render these fragments
sticky and, therefore, soluble antigen
may be more desirable. 
Production of soluble 
antibodies
The library is constructed to carry an
amber mutation; that is, instead of
reading through the antibody sequence
immediately into pIII to form a fusion
protein, the translation stops at the
amber mutation provided specific bacte-
rial hosts are used. It is therefore possible
to make secreted fragments; these are
soluble antibodies. The product has a
myc tail to aid detection; antibodies to
myc are available for use in immunoassay.
Avidity
The antibodies produced in un-immu-
nised humans are immature and may not
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be as avid as those derived from an
immunised individual. However, once
the phage of interest has been isolated,
Taq polymerase without proof-reading
capacity can be used in the polymerase
chain reaction to randomly introduce
base pair changes into the antibody
sequence. The PCR products can be re-
cloned into the phage, amplified, purified
and selected by panning. Individual
phages can then harvested, their anti-
body products being made as soluble
fragments and tested for avidity and
affinity. The most appropriate antibody
may then be selected and grown in bulk. 
Achievements 
and scope
We have already isolated monoclonal
antibodies recognising cell surface anti-
gens of several organisms involved in
sexually transmitted disease. A colleague
from the French West Indies isolated 14
antibodies recognising a clam-specific
protein in one month spent in our labo-
ratories. We are now working to produce
a robust system with a view to running
practical workshops in phage display
technology. We would envisage partici-
pants arriving with their antigen and two
weeks later returning to their laboratory
with antibodies. Have we whetted 
your appetite? Then why not contact 
us for more information by emailing
greenwp@wmin.ac.uk. n
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